| Abstract |
The Clinical Trial is investigating how well different types of cancer respond to the drug called Larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinbib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. There are currently no other standard forms of treatment that would be able to cure or effectively treat the ccancer concisting of this gene
|
| Link | |
| Subject |
Solid Tumors Harboring NTRK Fusion
|
| Title |
A phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in subjects with NTRK Fusion – Positive Tumors
|
| Type of document |
Interventional/Clinical trials research
|
| Entity Type |
Project
|
| Name | Size | format | Description | Link |
|---|